GRI Bio CEO, Marc Hertz, Participates in Virtual Investor 鈥淲hat This Means鈥� Segment
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators, announced CEO Marc Hertz's participation in a Virtual Investor "What This Means" segment. During the presentation, Dr. Hertz discussed the company's recently announced 6-week interim biomarker data from their ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (IPF).
GRI Bio (NASDAQ: GRI), un'azienda biotecnologica specializzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT), ha annunciato la partecipazione del CEO Marc Hertz a una sessione virtuale per investitori intitolata "What This Means". Durante la presentazione, il dott. Hertz ha illustrato i dati preliminari sui biomarcatori a 6 settimane recentemente annunciati derivanti dal loro studio di Fase 2a in corso sulla Fibrosi Polmonare Idiopatica (IPF).
GRI Bio (NASDAQ: GRI), una empresa biotecnol贸gica centrada en el desarrollo de moduladores de c茅lulas Natural Killer T (NKT), anunci贸 la participaci贸n del CEO Marc Hertz en un segmento virtual para inversores titulado "What This Means". Durante la presentaci贸n, el Dr. Hertz habl贸 sobre los datos interinos de biomarcadores a 6 semanas recientemente anunciados de su estudio en curso de Fase 2a en Fibrosis Pulmonar Idiop谩tica (IPF).
GRI Bio (NASDAQ: GRI)電� 鞛愳棸 靷错暣 T靹疙彫(NKT) 臁办爤鞝� 臧滊皽鞐� 欤茧牓頃橂姅 靸濍獏瓿淀暀 須岇偓搿�, CEO 毵堩伂 項堨笭臧� 臧�靸� 韴瀽鞛� 靹胳厴 "What This Means"鞐� 彀胳棳頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 氚滍憸 欷� 項堨笭 氚曥偓電� 韸闺皽靹� 韽愳劕鞙犾(IPF)鞚� 雽�靸侅溂搿� 歆勴枆 欷戩澑 2a靸� 鞐瓣惮鞐愳劀 斓滉芳 氚滍憸霅� 6欤检皑 欷戧皠 氚旍澊鞓る旎� 雿办澊韯�鞐� 雽�頃� 靹る獏頄堨姷雼堧嫟.
GRI Bio (NASDAQ: GRI), une soci茅t茅 de biotechnologie sp茅cialis茅e dans le d茅veloppement de modulateurs des cellules Natural Killer T (NKT), a annonc茅 la participation de son PDG Marc Hertz 脿 une session virtuelle pour investisseurs intitul茅e 芦 What This Means 禄. Lors de la pr茅sentation, le Dr Hertz a discut茅 des donn茅es interm茅diaires sur les biomarqueurs 脿 6 semaines r茅cemment annonc茅es issues de leur 茅tude de phase 2a en cours sur la fibrose pulmonaire idiopathique (IPF).
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Natural Killer T (NKT)-Zellmodulatoren spezialisiert hat, gab bekannt, dass CEO Marc Hertz an einem virtuellen Investoren-Segment "What This Means" teilnimmt. W盲hrend der Pr盲sentation erl盲uterte Dr. Hertz die k眉rzlich bekannt gegebenen 6-Wochen-Zwischendaten zu Biomarkern aus der laufenden Phase-2a-Studie zur idiopathischen Lungenfibrose (IPF).
- None.
- None.
LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GRI) (鈥淕RI Bio鈥� or the 鈥淐ompany鈥�), a biotechnology company advancing an innovative pipeline of Natural Killer T (鈥淣KT鈥�) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a .
For the segment, of GRI, discussed the Company鈥檚 recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (鈥淚PF鈥�).
The 鈥淲hat This Means鈥� segment can be accessed .
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio鈥檚 therapies are designed to target the activity of Natural Killer T (鈥淣KT鈥�) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (鈥渋NKT鈥�) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio鈥檚 lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (鈥渄NKT鈥�) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
FAQ
What did GRI Bio CEO discuss in the Virtual Investor segment?
What is GRI Bio's main focus in drug development?
What clinical trial is GRI Bio currently conducting?
Who is the CEO of GRI Bio (NASDAQ: GRI)?
